Pertussis medical therapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
(26 intermediate revisions by 6 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{CMG}}; {{AE}} {{ADI}}; {{Rim}}
{{CMG}}; {{AE}} {{SSK}}; {{YD}}
{{Pertussis}}
{{Pertussis}}
==Overview==
==Overview==
Early treatment of pertussis is very important. The earlier a person, especially an infant, starts treatment the better. A reasonable guideline is to treat persons aged >1 year within 3 weeks of cough onset and infants aged <1 year and pregnant women (especially near term) within 6 weeks of cough onset. The recommended antimicrobial agents for treatment or chemoprophylaxis of pertussis are [[azithromycin]], [[clarithromycin]] and [[erythromycin]]. [[Trimethoprim-sulfamethoxasole]] can also be used.  Consider using an alternative drug to [[azithromycin]] in those who have known [[cardiovascular disease]].<ref name=CDC4>[http://www.cdc.gov/pertussis/clinical/treatment.html Pertussis (whooping cough). Treatment. CDC.gov. Accessed on June 15, 2014]</ref>
The mainstay of treatment of pertussis is [[antibiotic]] therapy. Early treatment is essential: individuals aged >1 year should be treated within 3 weeks of cough onset, infants aged <1 year and pregnant women (especially near term) should be treated within 6 weeks of cough onset. The recommended antimicrobial agents for treatment of pertussis are [[macrolides]]. [[Trimethoprim-sulfamethoxasole]] is an alternative in those who do not tolerate [[macrolide]] antibiotics.<ref name="CDC4">Pertussis Treatment. Centers for Disease Control and Prevention (2016). http://www.cdc.gov/pertussis/clinical/treatment.html. Accessed on January 14, 2016.</ref>


==Medical Therapy==
==Medical Therapy==
* Early treatment of pertussis is very important. The earlier a person, especially an infant, starts treatment the better. If treatment for pertussis is started early in the course of illness, during the first 1 to 2 weeks before coughing paroxysms occur, symptoms may be lessened. Clinicians should strongly consider treating prior to test results if clinical history is strongly suggestive or patient is at risk for severe or complicated disease (e.g. infants). If the patient is diagnosed late, [[antibiotic]]s will not alter the course of the illness and, even without antibiotics, the patient should no longer be spreading pertussis.
*The mainstay of treatment of pertussis is [[antibiotic]] therapy.<ref name="pmid10609814">{{cite journal| author=Honein MA, Paulozzi LJ, Himelright IM, Lee B, Cragan JD, Patterson L et al.| title=Infantile hypertrophic pyloric stenosis after pertussis prophylaxis with erythromcyin: a case review and cohort study. | journal=Lancet | year= 1999 | volume= 354 | issue= 9196 | pages= 2101-5 | pmid=10609814 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10609814  }} </ref>


* Persons with pertussis are infectious from the beginning of the catarrhal stage ([[runny nose]], [[sneezing]], [[low-grade fever]], symptoms of the [[common cold]]) through the third week after the onset of paroxysms (multiple, rapid coughs) or until 5 days after the start of effective antimicrobial treatment.
===Timing===
*Early treatment of pertussis is very important.
*The earlier a person, especially an infant, starts treatment the better. If treatment for pertussis is started early in the course of illness, during the first 1 to 2 weeks before coughing paroxysms occur, symptoms may be lessened.
*Clinicians should strongly consider treating prior to test results if clinical history is strongly suggestive or patient is at risk for severe or complicated disease (e.g., infants).
*If the patient is diagnosed late, antibiotics will not alter the course of the illness and, even without antibiotics, the patient should no longer be spreading pertussis.
*It is recommended to treat persons older than 1 year of age within 3 weeks of cough onset and infants younger than 1 year of age and pregnant women (especially near term) within 6 weeks of cough onset.<ref name="CDC4">Pertussis Treatment. Centers for Disease Control and Prevention (2016). http://www.cdc.gov/pertussis/clinical/treatment.html. Accessed on January 14, 2016.</ref><ref name="pmid10609814">{{cite journal| author=Honein MA, Paulozzi LJ, Himelright IM, Lee B, Cragan JD, Patterson L et al.| title=Infantile hypertrophic pyloric stenosis after pertussis prophylaxis with erythromcyin: a case review and cohort study. | journal=Lancet | year= 1999 | volume= 354 | issue= 9196 | pages= 2101-5 | pmid=10609814 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10609814  }} </ref>


* A reasonable guideline is to treat persons aged >1 year within 3 weeks of cough onset and infants aged <1 year and pregnant women (especially near term) within 6 weeks of cough onset. The recommended antimicrobial agents for treatment or chemoprophylaxis of pertussis are [[azithromycin]], [[clarithromycin]] and [[erythromycin]]. [[Trimethoprim-sulfamethoxasole]] can also be used.
===Antimicrobial Regimens===
 
:* '''1.''' '''Whooping cough'''<ref name="pmid10609814">{{cite journal| author=Honein MA, Paulozzi LJ, Himelright IM, Lee B, Cragan JD, Patterson L et al.| title=Infantile hypertrophic pyloric stenosis after pertussis prophylaxis with erythromcyin: a case review and cohort study. | journal=Lancet | year= 1999 | volume= 354 | issue= 9196 | pages= 2101-5 | pmid=10609814 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10609814  }} </ref>
*The choice of antimicrobial should be made after consideration of the:
::* '''1.1.''' '''Adults'''
** Potential for adverse events and drug interactions
:::* Preferred regimen (1): [[Azithromycin]] 500 mg PO single dose on day 1 {{then}} 250 mg PO qd on 2-5 days
** Tolerability
:::* Preferred regimen (2): [[Erythromycin]] 2 g/day PO qid for 14 days
** Ease of adherence to the regimen prescribed
:::* Preferred regimen (3): [[Clarithromycin]] 1 g PO bid for 7 days
** Cost
:::* Alternative regimen (intolerant of macrolides): [[Trimethoprim-Sulfamethoxazole]] 320/1600 mg/day PO bid for 14 days
 
::* '''1.2.''' '''Infants <6 months of age'''
* On March 12, 2013, the Food and Drug Administration (FDA) issued a warning that [[azithromycin]] can cause abnormal changes in the electrical activity of the heart that may lead to a potentially fatal irregular heart rhythm in some patients.  [[Azithromycin]] remains one of the recommended drugs for treatment and chemoprophylaxis of pertussis, but consider using an alternative drug in those who have known cardiovascular disease, including:
:::* '''1.2.1.''' '''Infants <1 month'''
** Patients with known prolongation of the [[QT interval]], a history of [[torsades de pointes]], [[congenital long QT syndrome]], [[bradyarrhythmia]]s, or uncompensated [[heart failure]]
::::* Preferred regimen (1): [[Azithromycin]] 10 mg/kg PO qd for 5 days
** Patients on drugs known to prolong the QT interval
::::* Preferred regimen (2) (if azithromycin unavailable): [[Erythromycin]] 40-50 mg/kg/day PO q6h for 14 days
** Patients with ongoing proarrhythmic conditions such as uncorrected [[hypokalemia]] or [[hypomagnesemia]], clinically significant [[bradycardia]], and in patients receiving Class IA ([[quinidine]], [[procainamide]]) or Class III ([[dofetilide]], [[amiodarone]], [[sotalol]]) antiarrhythmic agents.
::::* Note: [[Trimethoprim-Sulfamethoxazole]] contraindicated for infants aged < 2 months
** Elderly patients and patients with cardiac disease may be more susceptible to the effects of arrhythmogenic drugs on the [[QT interval]].
:::* '''1.2.2.''' '''Infants of 1-5 months of age'''
 
::::* Preferred regimen (1): [[Azithromycin]] 10 mg/kg PO qd for 5 days
===Infants===
::::* Preferred regimen (2): [[Erythromycin]] 40-50 mg/kg/day PO qid for 14 days
====Age ≥1 Month====
::::* Preferred regimen (3): [[Clarithromycin]] 15 mg/kg PO bid for 7 days
* [[Erythromycin]], [[clarithromycin]], and [[azithromycin]] are preferred for the treatment of pertussis in persons ≥1 month of age.  
::::* Alternative regimen (for infants aged ≥ 2 months): [[Trimethoprim-Sulfamethoxazole]] 8/40 mg/kg/day PO bid for 14 days
* For persons ≥2 months of age, an alternative to [[macrolide]]s is [[trimethoprim-sulfamethoxazole]].
::* '''1.3.''' '''Infants ≥6 months of age-children'''
 
::::* Preferred regimen (1): [[Azithromycin]] 10 mg/kg PO single dose {{then}} 5 mg/kg PO qd for 2-5 days (maximum dose 500 mg/day)
====Age <1 Month====
::::* Preferred regimen (2): [[Erythromycin]] 40-50 mg/kg PO qid for 14 days (maximum dose 2 g/day)  
* For infants <1 month of age, [[azithromycin]] is preferred for post exposure prophylaxis and treatment because [[azithromycin]] has not been associated with [[infantile hypertrophic pyloric stenosis]] (IHPS), whereas [[erythromycin]] has.
::::* Preferred regimen (3): [[Clarithromycin]] 15 mg/kg PO bid for 7 days (maximum dose 1 g/day)  
* For infants <1 month of age, the risk of developing severe pertussis and life-threatening complications outweighs the potential risk of IHPS that has been associated with [[macrolide]] use.
::::* Preferred regimen (4): [[Trimethoprim-Sulfamethoxazole]] 8/40 mg/kg/day PO bid for 14 days
* Infants <1 month of age who receive a [[macrolide]] should be monitored for the development of IHPS and for other serious adverse events.
:* '''2.''' '''Post exposure prophylaxis'''<ref name="pmid10609814">{{cite journal| author=Honein MA, Paulozzi LJ, Himelright IM, Lee B, Cragan JD, Patterson L et al.| title=Infantile hypertrophic pyloric stenosis after pertussis prophylaxis with erythromcyin: a case review and cohort study. | journal=Lancet | year= 1999 | volume= 354 | issue= 9196 | pages= 2101-5 | pmid=10609814 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10609814  }} </ref>
::* Preferred regimen: The antibiotic regimens for post exposure prophylaxis are similar to the regimens used for the treatment of pertussis
::* Click [[Pertussis secondary prevention|here]] to learn more about postexposure prophylaxis.


==References==
==References==
Line 40: Line 47:
[[Category:Bacterial diseases]]
[[Category:Bacterial diseases]]
[[Category:Pediatrics]]
[[Category:Pediatrics]]
[[Category:Infectious diseases]]
[[Category:Infectious diseases Project]]
[[Category:Emergency medicine]]
[[Category:Pulmonology]]
[[Category:Pulmonology]]



Latest revision as of 17:25, 14 January 2016

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Serge Korjian M.D.; Yazan Daaboul, M.D.

Pertussis Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Pertussis from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Pertussis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Pertussis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pertussis medical therapy

CDC onPertussis medical therapy

Pertussis medical therapy in the news

Blogs on Pertussis medical therapy

Directions to Hospitals Treating Type page name here

Risk calculators and risk factors for Pertussis medical therapy

Overview

The mainstay of treatment of pertussis is antibiotic therapy. Early treatment is essential: individuals aged >1 year should be treated within 3 weeks of cough onset, infants aged <1 year and pregnant women (especially near term) should be treated within 6 weeks of cough onset. The recommended antimicrobial agents for treatment of pertussis are macrolides. Trimethoprim-sulfamethoxasole is an alternative in those who do not tolerate macrolide antibiotics.[1]

Medical Therapy

Timing

  • Early treatment of pertussis is very important.
  • The earlier a person, especially an infant, starts treatment the better. If treatment for pertussis is started early in the course of illness, during the first 1 to 2 weeks before coughing paroxysms occur, symptoms may be lessened.
  • Clinicians should strongly consider treating prior to test results if clinical history is strongly suggestive or patient is at risk for severe or complicated disease (e.g., infants).
  • If the patient is diagnosed late, antibiotics will not alter the course of the illness and, even without antibiotics, the patient should no longer be spreading pertussis.
  • It is recommended to treat persons older than 1 year of age within 3 weeks of cough onset and infants younger than 1 year of age and pregnant women (especially near term) within 6 weeks of cough onset.[1][2]

Antimicrobial Regimens

  • 1. Whooping cough[2]
  • 1.1. Adults
  • 1.2. Infants <6 months of age
  • 1.2.1. Infants <1 month
  • 1.2.2. Infants of 1-5 months of age
  • 1.3. Infants ≥6 months of age-children
  • Preferred regimen (1): Azithromycin 10 mg/kg PO single dose THEN 5 mg/kg PO qd for 2-5 days (maximum dose 500 mg/day)
  • Preferred regimen (2): Erythromycin 40-50 mg/kg PO qid for 14 days (maximum dose 2 g/day)
  • Preferred regimen (3): Clarithromycin 15 mg/kg PO bid for 7 days (maximum dose 1 g/day)
  • Preferred regimen (4): Trimethoprim-Sulfamethoxazole 8/40 mg/kg/day PO bid for 14 days
  • 2. Post exposure prophylaxis[2]
  • Preferred regimen: The antibiotic regimens for post exposure prophylaxis are similar to the regimens used for the treatment of pertussis
  • Click here to learn more about postexposure prophylaxis.

References

  1. 1.0 1.1 Pertussis Treatment. Centers for Disease Control and Prevention (2016). http://www.cdc.gov/pertussis/clinical/treatment.html. Accessed on January 14, 2016.
  2. 2.0 2.1 2.2 2.3 Honein MA, Paulozzi LJ, Himelright IM, Lee B, Cragan JD, Patterson L; et al. (1999). "Infantile hypertrophic pyloric stenosis after pertussis prophylaxis with erythromcyin: a case review and cohort study". Lancet. 354 (9196): 2101–5. PMID 10609814.


Template:WH Template:WS